Compare Stocks: ANL, AUPH, AGIO, and NBTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.47 -2.2%	$35.09	$22.24 ▼ $46.00	$2.00B	0.58	1.06 million shs	939,123 shs
ANL Adlai Nortye	$12.86 -1.8%	$11.37	$0.88 ▼ $17.25	$514.40M	1.06	412,418 shs	78,574 shs
AUPH Aurinia Pharmaceuticals	$15.18 -1.7%	$15.92	$10.34 ▼ $19.25	$2.02B	1.42	1.25 million shs	1.59 million shs
NBTX Nanobiotix	$38.17 -3.2%	$37.73	$7.87 ▼ $57.14	$1.93B	0.78	75,242 shs	107,008 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+4.65%	+7.90%	-15.64%	+19.07%	-3.31%
ANL Adlai Nortye	+0.08%	+0.15%	+41.67%	-5.56%	+700.61%
AUPH Aurinia Pharmaceuticals	+0.52%	+1.71%	-3.62%	-2.46%	+36.48%
NBTX Nanobiotix	+1.86%	-0.58%	+0.74%	-28.38%	+427.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.47 -2.2%	$35.09	$22.24 ▼ $46.00	$2.00B	0.58	1.06 million shs	939,123 shs
ANL Adlai Nortye	$12.86 -1.8%	$11.37	$0.88 ▼ $17.25	$514.40M	1.06	412,418 shs	78,574 shs
AUPH Aurinia Pharmaceuticals	$15.18 -1.7%	$15.92	$10.34 ▼ $19.25	$2.02B	1.42	1.25 million shs	1.59 million shs
NBTX Nanobiotix	$38.17 -3.2%	$37.73	$7.87 ▼ $57.14	$1.93B	0.78	75,242 shs	107,008 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+4.65%	+7.90%	-15.64%	+19.07%	-3.31%
ANL Adlai Nortye	+0.08%	+0.15%	+41.67%	-5.56%	+700.61%
AUPH Aurinia Pharmaceuticals	+0.52%	+1.71%	-3.62%	-2.46%	+36.48%
NBTX Nanobiotix	+1.86%	-0.58%	+0.74%	-28.38%	+427.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.40	Hold	$41.25	22.66% Upside
ANL Adlai Nortye	2.67	Moderate Buy	$24.25	90.57% Upside
AUPH Aurinia Pharmaceuticals	2.17	Hold	$17.67	16.80% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$37.33	-2.92% Downside

Current Analyst Ratings Breakdown

Latest ANL, AUPH, AGIO, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00
8/7/2026	AGIO Agios Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$31.00 ➝ $34.00
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $52.00
7/31/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $39.00
7/30/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $55.00
7/21/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$54.00 ➝ $52.00
7/21/2026	AUPH Aurinia Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2026	NBTX Nanobiotix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	AGIO Agios Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$28.00 ➝ $32.00
7/7/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $41.00

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$98.34M	20.42	N/A	N/A	$17.19 per share	1.96
ANL Adlai Nortye	$5M	101.80	N/A	N/A	($0.21) per share	-60.60
AUPH Aurinia Pharmaceuticals	$283.05M	7.11	$1.00 per share	15.17	$4.62 per share	3.27
NBTX Nanobiotix	$36.87M	52.80	N/A	N/A	($1.97) per share	-19.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	6.62	17.59	N/A	100.84%	26.11%	19.89%	N/A
NBTX Nanobiotix	-$27.11M	N/A	N/A	384.55	N/A	N/A	N/A	N/A	9/29/2026 (Estimated)

Latest ANL, AUPH, AGIO, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
ANL Adlai Nortye	N/A	0.65	0.65
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
NBTX Nanobiotix	N/A	1.09	1.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ANL Adlai Nortye	35.21%
AUPH Aurinia Pharmaceuticals	36.83%
NBTX Nanobiotix	38.81%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
ANL Adlai Nortye	N/A
AUPH Aurinia Pharmaceuticals	10.40%
NBTX Nanobiotix	3.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	59.70 million	56.48 million	Optionable
ANL Adlai Nortye	127	40.00 million	N/A	Not Optionable
AUPH Aurinia Pharmaceuticals	300	133.05 million	119.21 million	Optionable
NBTX Nanobiotix	100	50.62 million	48.87 million	Not Optionable

ANL, AUPH, AGIO, and NBTX Headlines

Recent News About These Companies

Nanobiotix SA Sponsored ADR

August 12 at 8:42 AM | edition.cnn.com

Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Here's What Happened

August 11 at 10:59 AM | marketbeat.com

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Receives $37.33 Average Price Target from Analysts

August 7, 2026 | americanbankingnews.com

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 2, 2026 | marketbeat.com

Voting Rights and Shares Capital of the Company

July 30, 2026 | globenewswire.com

Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.4% - What's Next?

July 20, 2026 | marketbeat.com

Nanobiotix (NASDAQ:NBTX) Sees Strong Trading Volume - Here's Why

July 17, 2026 | marketbeat.com

Nanobiotix (NASDAQ:NBTX) Shares Gap Down - What's Next?

July 15, 2026 | marketbeat.com

Nanobiotix (NASDAQ:NBTX) Shares Up 7.2% - Time to Buy?

July 14, 2026 | marketbeat.com

Nanobiotix Updates Share Capital and Voting Rights as of March 31, 2026

July 6, 2026 | theglobeandmail.com

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

June 25, 2026 | seekingalpha.com

Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech

June 12, 2026 | seekingalpha.com

Voting Rights and Shares Capital of the Company

June 5, 2026 | globenewswire.com

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

June 2, 2026 | globenewswire.com

Nanobiotix Joins the Euronext Tech Leaders Index

June 2, 2026 | globenewswire.com

NANOBIOTIX Announces Closing of Global Offering

May 26, 2026 | globenewswire.com

NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

May 23, 2026 | markets.businessinsider.com

NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

May 22, 2026 | globenewswire.com

Nanobiotix stock slides on $87M follow-on offering

May 21, 2026 | seekingalpha.com

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

May 21, 2026 | globenewswire.com

Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

May 21, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, AUPH, AGIO, and NBTX Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$33.47 -0.74 (-2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$33.47 +0.00 (+0.00%)

As of 05:31 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Adlai Nortye NASDAQ:ANL

$12.86 -0.23 (-1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$12.90 +0.04 (+0.35%)

As of 04:13 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Aurinia Pharmaceuticals NASDAQ:AUPH

$15.18 -0.27 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$15.15 -0.03 (-0.20%)

As of 06:05 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Nanobiotix NASDAQ:NBTX

$38.17 -1.27 (-3.22%)

Closing price 04:00 PM Eastern

Extended Trading

$38.31 +0.14 (+0.37%)

As of 04:10 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, AUPH, AGIO, and NBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, AUPH, AGIO, and NBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, AUPH, AGIO, and NBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, AUPH, AGIO, and NBTX Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Adlai Nortye NASDAQ:ANL

Aurinia Pharmaceuticals NASDAQ:AUPH

Nanobiotix NASDAQ:NBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, AUPH, AGIO, and NBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, AUPH, AGIO, and NBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, AUPH, AGIO, and NBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, AUPH, AGIO, and NBTX Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Adlai Nortye NASDAQ:ANL

Aurinia Pharmaceuticals NASDAQ:AUPH

Nanobiotix NASDAQ:NBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools